Compare BEEP & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEEP | CPIX |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.5M | 73.6M |
| IPO Year | 2021 | 2007 |
| Metric | BEEP | CPIX |
|---|---|---|
| Price | $2.07 | $3.23 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | 23.6K | ★ 42.4K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.70 |
| EPS | N/A | ★ N/A |
| Revenue | $35,075,000.00 | ★ $42,010,949.00 |
| Revenue This Year | $5.77 | N/A |
| Revenue Next Year | $22.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.75 |
| 52 Week Low | $2.00 | $1.85 |
| 52 Week High | $4.67 | $6.27 |
| Indicator | BEEP | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 48.86 |
| Support Level | $2.00 | $2.97 |
| Resistance Level | $3.24 | $3.69 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 16.28 | 52.81 |
Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.